rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ALNY
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Alnylam Pharmaceuticals stock hits 52-week low at 149.17 USD
      9h agoInvesting.comALNY
      JPMorgan cuts Alnylam stock price target on Amvuttra forecast
      15h agoInvesting.comALNY
      Alnylam at Jefferies Global Healthcare Conference: growth meets payer pressure
      18h agoInvesting.comALNY
      What Is Driving Alnylam Stock?
      Nov 16Yahoo FinanceALNY
      What Moved Alnylam Stock?
      Nov 12Yahoo FinanceALNY
      Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD

      CAMBRIDGE, Mass., November 10, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that we

      Nov 10Yahoo FinanceALNYREGN
      Alnylam Pharmaceuticals stock hits 52-week low at $155.22
      Nov 6Investing.comALNY
      Alnylam Pharmaceuticals announces $1 billion stock repurchase program and executive departure
      Nov 5Investing.comALNY
      Top 3 Health Care Stocks You'll Regret Missing In Q4
      Nov 5BenzingaALNYCORT
      Alnylam authorizes $1 billion share buyback program
      Nov 4Investing.comALNY
      Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership

      CAMBRIDGE, Mass., November 04, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters its next phase of growth.

      Nov 4Yahoo FinanceALNY
      What Could Alnylam Pharmaceuticals (ALNY) Five Year HELIOS B Data Change?
      Nov 4Yahoo FinanceALNY
      Alnylam downgraded at Truist on Amvuttra outlook

      Truist cut Alnylam to hold on Amvuttra sales uncertainty, lowering forecasts and price target. Read more here.

      Nov 2Seeking AlphaALNYTFC
      Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
      Nov 2Yahoo FinanceALNYAZNREGN
      FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight
      Nov 2Yahoo FinanceALNYCAPRREGN
      Alnylam (ALNY) Stock Drops As Q3 Earnings Clash With Sales Concerns
      Oct 31Yahoo FinanceALNY
      Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease - Slideshow (NASDAQ:ALNY) 2026-10-30

      2026-10-30. The following slide deck was published by Alnylam Pharmaceuticals, Inc.

      Oct 30Seeking AlphaALNY
      Freedom Broker cuts Alnylam stock price target on execution risks
      Oct 30Investing.comALNY
      Alnylam Faces Near-Term Risk on Amvuttra, Oppenheimer Says
      Oct 30Yahoo FinanceALNY
      Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS Says

      Alnylam Pharmaceuticals' (ALNY) fundamentals remain strong despite the company's expectation of 2026

      Oct 30Yahoo FinanceALNYUBS
      What Just Happened To Alnylam Stock?
      Oct 30Yahoo FinanceALNY
      Alnylam Q3 Update Disappoints as TTR Revenue Trends Toward Low End, RBC Says
      Oct 30Yahoo FinanceALNY
      UBS cuts Alnylam stock price target on Amvuttra outlook to $329
      Oct 30Investing.comALNY
      Alnylam Pharma stock downgraded at Bernstein (ALNY:NASDAQ)
      Oct 30Seeking AlphaALNY
      Oppenheimer Adjusts Price Target on Alnylam Pharmaceuticals to $320 From $350, Keeps Outperform Rating
      Oct 30Yahoo FinanceALNY
      This Honeywell Aerospace Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
      Oct 30BenzingaALNYHONHONA
      BMO cuts Alnylam stock price target on near-term headwinds
      Oct 30Investing.comALNY
      BofA cuts Alnylam stock price target on slower demand growth
      Oct 30Investing.comALNY
      Raymond James cuts Alnylam stock rating on Amvuttra uncertainty
      Oct 30Investing.comALNY
      What Investors Got Wrong About Alnylam Pharmaceuticals Before A 61% Slide
      Oct 30Yahoo FinanceALNY
      Alnylam Pharmaceuticals Inc (ALNY) (Q3 2026) Earnings Call Highlights: TTR Franchise Surges 59% ...
      Oct 29Yahoo FinanceALNY
      Alnylam Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Oct 29Yahoo FinanceALNY
      ALNY Stock Hits Fresh 52-Week Low On Medicare Access Worries And Pipeline Delays
      Oct 29Yahoo FinanceALNY
      Alnylam Pharmaceuticals Q3 Earnings Call Highlights
      Oct 29Yahoo FinanceALNY
      Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction”
      Oct 29Yahoo FinanceALNY
      Stifel downgrades Alnylam stock rating on Amvuttra concerns
      Oct 29Investing.comALNY
      Alnylam falls despite earnings beats as US Amvuttra, Onpattro sales growth slows

      Alnylam stock plunged after Q3 earnings beat as US Amvuttra demand slowed and costs rose. Read more here.

      Oct 29Seeking AlphaALNY
      Alnylam Q3 2026 slides: strong growth tempered by execution concerns
      Oct 29Investing.comALNY
      Alnylam Pharmaceuticals stock hits 52-week low at $187.12
      Oct 29Investing.comALNY
      Earnings call transcript: Alnylam beats Q3 2026 estimates, shares sink 17%
      Oct 29Investing.comALNY
      Alnylam Pharmaceuticals Q3 2026 Earnings Call Transcript - Alnylam Pharmaceuticals (NASDAQ:ALNY)

      Alnylam Pharmaceuticals (NASDAQ:ALNY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by

      Oct 29BenzingaALNY
      Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates

      Alnylam (ALNY) delivered earnings and revenue surprises of +642.47% and +0.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Oct 29Yahoo FinanceALNY
      Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
      Oct 29Yahoo FinanceALNY
      Alnylam Pharmaceuticals Q3 Non-GAAP Net Income, Revenue Rise; Fiscal 2026 Net Product Sales Outlook Kept
      Oct 29Yahoo FinanceALNY
      Alnylam earnings beat by $14.52, revenue topped estimates
      Oct 29Investing.comALNY
      Alnylam: Q3 Earnings Snapshot
      Oct 29Yahoo FinanceALNY
      Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
      Oct 29Yahoo FinanceALNY
      What Alnylam Pharmaceuticals (ALNY)'s Huntingtons Drug Trial Results Mean For Shareholders
      Oct 28Yahoo FinanceALNY
      Alnylam Pharmaceuticals (ALNY) Stock Looks Fully Priced Following Its 52% Fall
      Oct 28Yahoo FinanceALNY
      Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued Following Brezosiran Data
      Oct 28Yahoo FinanceALNY

      This is the newest page. Registered accounts read further back.